Welcome


Latest News



Welcome


NeuroSolis is a newly formed drug development company with an exclusive focus on neurological and psychiatric disorders having large unmet therapeutic needs. Our mission is to advance drug candidates through preclinical development into human trials. NeuroSolis is currently developing clinical candidate NSX-0527 for Alzheimer's disease and schizophrenia. We are seeking early-stage investors to participate in this endeavor. Additionally, we have open positions in our management and scientific teams. For more information, please email us at: query@neurosolis.com.



Latest News


8.22.17 - Patent for Clinical Candidate NSX-0527

The Unites States Patent and Trademark Office has issued US Patent 9,738,633 to NeuroSolis, Inc. This patent covers the synthesis and use of clinical candidate NSX-0527 and related compounds.








11.14.16 - 2016 Annual Meeting of the Society of Neuroscience

The NeuroSolis team presented results on the combination dosing of NSX-0527 and an FDA-approved muscarinic antagonist at the 46th Annual Society for Neuroscience Conference in San Diego, CA.









10.21.15 - 2015 Annual Meeting of the Society of Neuroscience

NeuroSolis presented data on the antipsychotic potenetial of NSX-0527 at the 45th Annual Society for Neuroscience Conference in Chicago, IL.









7.20.15 - Alzheimer's Association International Conference (AAIC) 2015

NeuroSolis scientists had a poster on NSX-0527 at the 2015 Alzheimer's Association International Conference in Washington, DC.









12.01.14 - Annual Meeting of the Society of Neuroscience

The NeuroSolis team presented preclinical results for NSX-0527 at the 44th Annual Society for Neuroscience Conference in Washington, DC.








10.7.14 - Patent for Clinical Candidate NSX-0527

The Unites States Patent and Trademark Office has issued US Patent 8,853,219 to NeuroSolis, Inc. This composition-of-matter patent covers clinical candidate NSX-0527 and related compounds.








5.14.14 - 2014 Governor's Business Plan Contest

NeuroSolis was selected as a finalist in the 2014 Wisconsin Governor's Business Plan contest out of nearly 300 entries.